Study finds melatonin eases sleep woes in children with autism

January 9, 2012

(Medical Xpress) -- A new Vanderbilt study shows that the over-the-counter supplement melatonin is promising in helping children with autism spectrum disorders (ASD), and their families, sleep better.

The study, published in the , contributes to the growing literature on supplemental for in ASD, according to lead author Beth Malow, M.D., M.S., professor of Neurology and Pediatrics, Burry Chair in Cognitive and Vanderbilt Kennedy Center investigator.

Malow said the study was designed to allow researchers to identify doses at which children responded to melatonin and also how long it took to observe a response.

, particularly insomnia, occur in 50 percent to 80 percent of children with ASD and are often accompanied by child and family distress.

“We are excited about the potential melatonin has for treating insomnia, which can be overwhelming to children with autism as well as their families,” Malow said. “The next step is to perform large-scale, controlled trials to prove that melatonin is effective in this population.”

Malow and colleagues recruited children ages 3-9 years with a clinical diagnosis of an ASD whose parents reported sleep onset delay of 30 minutes or longer on three or more nights per week.

Supplemental melatonin, given 30 minutes before bedtime, improved sleep latency in most children at 1 mg or 3 mg dosages.

Sleep latency, or the amount of time it takes a child to fall asleep, was measured by using an actigraph, which is a wrist-watch-like sensor worn by participants to monitor human rest/activity cycles.

Melatonin was effective in the first week of treatment, maintained effectiveness over several months, was well-tolerated and safe, and showed improvement in sleep, behavior and parenting stress, Malow said.

“While supplemental melatonin has shown promise in treating insomnia in our work and those of others, it is important that individuals with insomnia seek medical advice before taking melatonin,” Malow said. “This is because other treatable medical and sleep conditions can sometimes cause insomnia. Also, melatonin can interact with other drugs for other medical conditions."

Explore further: Tireless research reveals secrets of the 'sleep hormone'

Related Stories

Tireless research reveals secrets of the 'sleep hormone'

December 13, 2011
A team from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University has made a major breakthrough by unraveling the inner workings of melatonin, also known as the "sleep hormone." The ...

Recommended for you

Signaling pathway may be key to why autism is more common in boys

October 17, 2017
Researchers aiming to understand why autism spectrum disorders (ASD) are more common in boys have discovered differences in a brain signaling pathway involved in reward learning and motivation that make male mice more vulnerable ...

Whole genome sequencing identifies new genetic signature for autism

October 12, 2017
Autism has genetic roots, but most cases can't be explained by current genetic tests.

Mum's immune response could trigger social deficits for kids with autism

October 10, 2017
The retrospective cohort study of 220 Australian children, conducted between 2011-2014, indicates that a "an immune-mediated subtype" of autism driven by the body's inflammatory and immunological systems may be pivotal, according ...

Largest study to date reveals gender-specific risk of autism occurrence among siblings

September 25, 2017
Having one child with autism is a well-known risk factor for having another one with the same disorder, but whether and how a sibling's gender influences this risk has remained largely unknown.

Faulty cell signaling derails cerebral cortex development, could it lead to autism?

September 20, 2017
As the embryonic brain develops, an incredibly complex cascade of cellular events occur, starting with progenitors - the originating cells that generate neurons and spur proper cortex development. If this cascade malfunctions ...

Predicting atypical development in infants at high risk for autism?

September 12, 2017
New research from the Sackler Institute for Developmental Psychobiology at Columbia University Medical Center (CUMC) identifies a potential biomarker that predicts atypical development in 1- to 2-month-old infants at high ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.